Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

DarioHealth Corp (DRIO)DRIO

Upturn stock ratingUpturn stock rating
DarioHealth Corp
$0.97
Delayed price
Profit since last BUY-13.39%
WEAK BUY
upturn advisory
BUY since 29 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/07/2024: DRIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: WEAK BUY
Historic Profit: -67.87%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 22
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/07/2024
Type: Stock
Today’s Advisory: WEAK BUY
Historic Profit: -67.87%
Avg. Invested days: 22
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/07/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 28.82M USD
Price to earnings Ratio -
1Y Target Price 3.83
Dividends yield (FY) -
Basic EPS (TTM) -1.17
Volume (30-day avg) 79196
Beta 1.51
52 Weeks Range 0.70 - 2.60
Updated Date 11/8/2024
Company Size Small-Cap Stock
Market Capitalization 28.82M USD
Price to earnings Ratio -
1Y Target Price 3.83
Dividends yield (FY) -
Basic EPS (TTM) -1.17
Volume (30-day avg) 79196
Beta 1.51
52 Weeks Range 0.70 - 2.60
Updated Date 11/8/2024

Earnings Date

Report Date 2024-11-07
When BeforeMarket
Estimate -0.27
Actual -0.25
Report Date 2024-11-07
When BeforeMarket
Estimate -0.27
Actual -0.25

Profitability

Profit Margin -205.62%
Operating Margin (TTM) -162.06%

Management Effectiveness

Return on Assets (TTM) -34.74%
Return on Equity (TTM) -74.91%

Revenue by Products

Revenue by Products - Current and Previous Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 38085453
Price to Sales(TTM) 1.25
Enterprise Value to Revenue 1.99
Enterprise Value to EBITDA -0.59
Shares Outstanding 31323900
Shares Floating 28065392
Percent Insiders 19.26
Percent Institutions 25.36
Trailing PE -
Forward PE -
Enterprise Value 38085453
Price to Sales(TTM) 1.25
Enterprise Value to Revenue 1.99
Enterprise Value to EBITDA -0.59
Shares Outstanding 31323900
Shares Floating 28065392
Percent Insiders 19.26
Percent Institutions 25.36

Analyst Ratings

Rating 5
Target Price 7.82
Buy -
Strong Buy 3
Hold -
Sell -
Strong Sell -
Rating 5
Target Price 7.82
Buy -
Strong Buy 3
Hold -
Sell -
Strong Sell -

AI Summarization

DarioHealth Corp. (DRIO): A Comprehensive Overview

Company Profile:

  • Founded: 2011 (formerly IHealth)
  • Headquarters: New York, NY
  • CEO: Rick Anderson
  • President: Erez Raphael
  • Business: Provider of AI-powered, personalized chronic disease management solutions

Products and Market Share:

  • Dario Smart Diabetes Management System: Combines a Bluetooth-connected blood glucose meter, app, and coaching features.

  • Dario Blood Glucose Meter: Affordable, single-use meter for measuring blood glucose levels.

  • Dario for Hypertension: AI-powered app for managing hypertension.

  • Dario for Irritable Bowel Syndrome (IBS): App for managing IBS symptoms.

  • Market Share: 0.2% market share in the global diabetes management market.

  • Competitors: Dexcom, Abbott Laboratories, Teladoc Health, Livongo Health, Omada Health.

Total Addressable Market:

  • Global diabetes management market: $60 billion
  • US diabetes management market: $40 billion

Financial Performance:

  • Revenue: $34.3 million in 2022, $19.0 million in 2021.
  • Net Loss: $19.9 million in 2022, $18.0 million in 2021.
  • Margins: Gross margin 60.7%, Operating margin -63.0%
  • EPS: Loss per share of $1.90 in 2022, Loss per share of $1.70 in 2021.

Dividends and Shareholder Returns:

  • No dividend history, company is focused on growth.
  • Shareholder returns: -69.1% in 2022, -40.6% in 2023 (YTD).

Growth Trajectory:

  • Revenue growth slowed down in 2022 compared to 2021.
  • Company projects revenue growth of 40-50% in 2023.
  • Growth drivers: new product launches, partnerships, and expansion into new markets.

Market Dynamics:

  • Increasing prevalence of chronic diseases.
  • Growing adoption of digital health solutions.
  • Competition from established players and new entrants.

Competitors:

  • Dexcom (DXCM): Market share: 40.8%
  • Abbott Laboratories (ABT): Market share: 20.0%
  • Teladoc Health (TDOC): Market share: 10.0%
  • Livongo Health (LVGO): Market share: 4.0%
  • Omada Health (OMH): Market share: 3.0%

Potential Challenges and Opportunities:

  • Challenges: Competition, scalability, profitability.
  • Opportunities: Growing market, product innovation, strategic partnerships.

Recent Acquisitions:

  • Nutrino Health Ltd. (2021): Acquired for $50 million. Nutrino's AI-powered platform will enhance Dario's personalized nutrition recommendations.
  • Sweetch (2020): Acquired for $5 million. Sweetch's mobile app helps manage type 2 diabetes through personalized coaching and gamification.

AI-Based Fundamental Rating:

  • Rating: 6/10
  • Justification: DarioHealth has a promising product portfolio and operates in a growing market. However, the company is not yet profitable and faces intense competition.

Sources and Disclaimers:

  • Company website: https://dariohealth.com/
  • Market research reports: Statista, Grand View Research
  • Financial data: Reuters, Yahoo Finance

Disclaimer: This information is for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.

Additional Notes:

  • This analysis is based on publicly available information as of November 21, 2023.
  • The company's stock price is volatile and can fluctuate significantly.
  • Investors should carefully consider their own risk tolerance and financial situation before investing in DarioHealth Corp.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About DarioHealth Corp

Exchange NASDAQ Headquaters New York, NY, United States
IPO Launch date 2014-10-06 CEO & Director Mr. Erez Raphael
Sector Healthcare Website https://www.dariohealth.com
Industry Health Information Services Full time employees 276
Headquaters New York, NY, United States
CEO & Director Mr. Erez Raphael
Website https://www.dariohealth.com
Website https://www.dariohealth.com
Full time employees 276

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​